1. 420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study. (10th December 2020) Authors: Diab, Adi; Tykodi, Scott; Daniels, Gregory; Maio, Michele; Curti, Brendan; Lewis, Karl; Jang, Sekwon; Kalinka, Ewa; Puzanov, Igor; Spira, Alexander; Cho, Daniel; Guan, Shanhong; Puente, Erika; Hoch, Ute; Currie, Sue; Nguyen, Tuan; Lin, Wei; Tagliaferri, Mary; Zalevsky, Jonathan; Sznol, Mario Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A256 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study. (9th November 2020) Authors: Diab, Adi; Tykodi, Scott; Daniels, Gregory; Maio, Michele; Curti, Brendan; Lewis, Karl; Jang, Sekwon; Kalinka, Ewa; Puzanov, Igor; Spira, Alexander; Cho, Daniel; Guan, Shanhong; Puente, Erika; Hoch, Ute; Currie, Sue; Nguyen, Tuan; Lin, Wei; Tagliaferri, Mary; Zalevsky, Jonathan; Sznol, Mario Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A446 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. Issue 26 (10th September 2021) Authors: Diab, Adi; Tykodi, Scott S.; Daniels, Gregory A.; Maio, Michele; Curti, Brendan D.; Lewis, Karl D.; Jang, Sekwon; Kalinka, Ewa; Puzanov, Igor; Spira, Alexander I.; Cho, Daniel C.; Guan, Shanhong; Puente, Erika; Nguyen, Tuan; Hoch, Ute; Currie, Sue L.; Lin, Wei; Tagliaferri, Mary A.; Zalevsky, Jon... Journal: Journal of clinical oncology Issue: Volume 39:Issue 26(2021) Page Start: 2914 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. Issue 4 (20th April 2022) Authors: Tannir, Nizar M; Cho, Daniel C; Diab, Adi; Sznol, Mario; Bilen, Mehmet A; Balar, Arjun V; Grignani, Giovanni; Puente, Erika; Tang, Lily; Chien, David; Hoch, Ute; Choudhury, Arkopal; Yu, Danni; Currie, Sue L; Tagliaferri, Mary A; Zalevsky, Jonathan; Siefker-Radtke, Arlene O; Hurwitz, Michael E Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 4(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗